CN V3 Blog - Related

Ponatinib plus blinatumomab may help “a meaningful subset of patients” forego transplant for Ph-positive acute lymphoblastic leukemia.

Ursula A. Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a positive study.

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and sexual health.

Ursula A. Matulonis, MD, discussed how biomarkers, adverse effects, and patient preference guide choices among recent platinum-resistant ovarian cancer approvals.

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

Dr. Andrew Pecora on leading the first IV oncolytic virus trial, building a top-50 cancer center, and using AI to fix the cost of cancer care.

Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.